A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety, Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, an Intravenous Fenretinide Phospholipid Suspension (12.5 mg/mL)

Authors

• Oleg E. Akilov
• Auris O. Huen
• Barbara Pro
• Dipenkumar Modi
• Ann F. Mohrbacher
• Brad M. Haverkos
• Aaron R. Mangold
• Christiane Querfeld
• Ryan A. Wilcox
• Louis M. Scarmoutzos
• Michael Burns
• Earle T. Holsapple
• Kenneth D. Massey
• Ralph E. Parchment
• Yamini Donekal
• Ali Moiin, Corewell Health East

Document Type

Conference Proceeding

Publication Date

10-2025

Publication Title

European Journal of Cancer

Volume

229

Issue

S1

First Page

S26

Last Page

S27

Recommended Citation

Akilov OE, Huen AO, Pro B, Modi D, Mohrbacher AF, Haverkos BM, et al. [Moiin A]. A phase 1a/1b trial in relapsed/refractory T-cell non-Hodgkin lymphoma to determine the safety, profile, pharmacology, and maximum tolerated dose of ST-001, an intravenous fenretinide phospholipid suspension (12.5 mg/mL). Eur J Cancer. 2025 Oct;229(S1):S26-S27. doi:10.1016/j.ejca.2025.115879

Comments

European Organisation for Research and Treatment of Cancer - Cutaneous Lymphoma Tumor Group (EORTC-CLTG) Annual Meeting, October 16-18, 2025, Athens, Greece

DOI

10.1016/j.ejca.2025.115879